01—Abstract
Summary
Summary of the 8-K filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Biogen Inc. (Nasdaq: BIIB) announced on October 28, 2024 that Chief Financial Officer Michael McDonnell will retire effective February 28, 2025.
Robin Kramer, the company's current Chief Accounting Officer and head of Global Business Services and Treasury, will succeed him as CFO upon his retirement. The 8-K was filed to disclose this leadership change under Item 5.02 (departure and appointment of certain officers) and to furnish the related press release under Item 7.01 (Regulation FD). The announcement is a planned succession rather than an abrupt departure, and McDonnell is staying on through the transition period to support a handover.
McDonnell has served as CFO since August 2020 and is credited by CEO Christopher Viehbacher with leading the "Fit for Growth" program to realign Biogen's cost structure with its revenue base, redeploying capital toward growth areas, and supporting recent late-stage asset acquisitions. Kramer, age 59, joined Biogen in 2018 and has held the Chief Accounting Officer role since 2020, giving her deep familiarity with the company's finance, treasury, procurement, and M&A work. Her background includes senior finance roles at Hertz, Fisher Scientific, and The Gillette Company, and prior audit partner positions at Deloitte, Ernst & Young, and Arthur Andersen.
For investors, the filing signals continuity rather than a strategic shift: the successor is an internal candidate with direct exposure to the company's capital allocation and M&A activity. Compensation terms set for Kramer include a $750,000a base salary, an 80% target bonus, and a 2025 long-term incentive target of $3.75 million, along with a tiered severance framework tied to termination and change-in-control scenarios. The filing does not disclose any change in financial guidance or results.
02—Key points
Key Highlights
- CFO Michael McDonnell will retire effective February 28, 2025, after serving in the role since August 2020.
- Robin Kramer, currently SVP and Chief Accounting Officer, will become CFO upon McDonnell's retirement; she will also join the Executive Committee.
- McDonnell is credited with leading the Fit for Growth cost realignment program and supporting recent late-stage acquisitions and financial discipline.
- Kramer's compensation: $750,000 base salary, 80% target annual bonus, and $3.75 million target 2025 long-term incentive grant value.
- Kramer's severance under the EVP plan is a minimum of 12 months of salary plus target bonus, rising to 21 months with service; a change-in-control termination within two years triggers 2x salary plus target bonus.
- The transition is planned and internal, with McDonnell working alongside Kramer in the coming months, which suggests limited execution risk.
- The filing contains no changes to financial guidance, results, or pipeline; the press release was furnished under Item 7.01 and not deemed filed under the Exchange Act.
03—Questions
Frequently Asked Questions
Why is Michael McDonnell retiring, and is the departure unexpected?
The company did not disclose a reason beyond McDonnell's stated desire to retire and spend more time with family. The announcement was made with a planned effective date about four months out, and McDonnell will work with Kramer on the transition, which points to an orderly succession rather than a forced departure.
Who is Robin Kramer and what experience does she bring to the CFO role?
Kramer, 59, joined Biogen in 2018 and has been Chief Accounting Officer since 2020, overseeing finance functions, Treasury, procurement, and Global Business Services. She has also worked on M&A strategy with McDonnell. Her prior roles include senior finance positions at Hertz, Fisher Scientific, and The Gillette Company, and audit partner roles at Deloitte, Ernst & Young, and Arthur Andersen. She is a licensed CPA in Massachusetts.
Does this leadership change affect Biogen's financial outlook or strategy?
The filing does not indicate any change to guidance, financial results, or strategy. CEO Christopher Viehbacher said Kramer's knowledge of the business gives him confidence in continuity with the company's transformation and growth objectives, and her involvement in past M&A and capital allocation decisions suggests strategic continuity.
What compensation and severance terms apply to the new CFO?
Kramer's base salary will be $750,000, with an annual bonus target of 80% of base salary and a 2025 long-term incentive target grant value of $3.75 million. Under the EVP severance plan, a termination other than for cause (not due to death or disability) yields a lump sum of at least 12 months of salary plus target bonus, rising by two months per full year of service to a maximum of 21 months. Within two years after a change in control, the benefit is two times salary plus target bonus, along with continued medical and dental coverage. The full terms are in Exhibit 10.1.
04—Continue